Abbott reports fourth-quarter sales that miss analysts’ estimates.

ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories stock has reached a 52-week low, closing at $107.27. This marks a notable point for the healthcare company, as it navigates a challenging market environment. Over the past year, ...

Investing.com -- Abbott Laboratories (NYSE:ABT) reported fourth-quarter earnings that met expectations but missed on revenue, ...

Abbott Laboratories (ABT) on Thursday reported fourth-quarter net income of $1.78 billion. The Abbott Park, Illinois-based ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

Abbott received CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms. Shares of Abbott fell 0.3% to close at $120.73 on Wed ...

This was the stock's fourth consecutive day of losses.